Our Team

Jonathan Cohen

Founder, CEO

Jonathan Cohen is the founder, president, and CEO of 20/20 GeneSystems. Under Mr. Cohen’s leadership, 20/20 has brought in approximately $7.5 million in grant funding and launched two successful products, a bio-detection kit for suspicious powders used by hundreds of emergency responder organizations worldwide and a blood test for the early detection of lung cancer. He is the co-inventor of an AI approach for improving tumor biomarker accuracy that is covered in a pending PCT International Patent Application.

Michael S. Lebowitz, PhD

Chief Scientific Officer

Dr. Lebowitz has more than 18 years of experience in biomedical research within the biotech industry having previously served as Vice President of Research at Ariadne Diagnostics, LLC. He has been directly involved in the commercial launch of six cancer diagnostic tests and the research leading up to a pharmaceutical IND approval. Dr. Lebowitz holds a Ph.D. from the Johns Hopkins University School of Medicine in Biochemistry, Cellular, and Molecular Biology where he subsequently completed a three-year fellowship in immunology in the Department of Pathology, Division of Immunopathology.

Jiming Zhou


Dr. Zhou graduated from Sichuan University (China) and served as an Associate Professor before moving to the US, conducting academic research at University of Iowa, focusing on lung cancer and other disorders. Dr. Zhou then joined industrial R&D, led a joint pharmaceutical project total milestones of $330 million. From 2009, Dr. Zhou directed 2 independent clinical labs and co-funded 2 companies, worked with many large US and Chinese public and private healthcare institutes in multiple projects. Dr. Zhou published 20+ peer-reviewed manuscripts and owns several patents.

Jeffrey Allard, PhD


Dr. Allard is a biochemist and is President of Lakeside Life Science, which provides consulting services and biospecimens to the biotechnology industry. He served most recently as Director of Development for Caris Life Sciences, where he designed and implemented a Product Development System, designed multiple clinical and regulatory strategies for novel multiplex oncology tests, wrote clinical protocols for prospective research and Premarket Approval (PMA)-submission trials, and designed a patient registry.

Michael Ross,

Board Member

Dr. Ross is the Chairman and CEO of Euclid Systems Corporation (Herndon, VA) where he led the growth of this ophthalmic medical device company from $3.1 million to over $8.1 million in revenue in only years. The bulk of Euclid’s sales are in China and East Asia where Michael visits 4-5 times per year. Prior to joining Euclid, he was CEO of E-P Therapeutics, and was a Medical and Scientific Advisor to StemCyte, Inc. Michael was elected to the board of the Generic Pharmaceuticals Association by his peers after only two years in the industry. Board certified in Obstetrics and Gynecology he was a founding member of a OB-GYN-Infertility practice in Northern Virginia.